Prostate Cancer: A State of The Heart

Summary of Presentations from the Ferring Pharmaceuticals Sponsored Symposium, held at the 29th Annual EAU Congress, Stockholm, Sweden, on 13th April 2014

Chairperson: Laurence Klotz1
Speakers: Alberto Briganti,2 Jan Nilsson,3 Alexandre de la Taille4

1. University of Toronto, Toronto, Canada
2. University Vita-Salute San Raffaele, Milan, Italy
3. University of Lund, Malmö, Sweden
4. CHU Mondor, Créteil, France

Disclosure: LK – Speaker or advisor: Amgen, Astellas, Dendreon, Ferring, GSK, Janssen, Profound Medical, and Sanofi Aventis; AB – Nothing to disclose; AdlT – Consultant or advisor: Astellas, Ferring, Ipsen, Takeda, and PFM; JN – Consultant or advisor: Boehringer Ingelheim, Probi AB.
Acknowledgements: Writing assistance provided by Dr Tabasum Mughal.
Support: Ferring Pharmaceuticals sponsored this symposium. The views and opinions expressed are those of the authors.
Citation: EMJ Urol. 2014;1:48-53.

Meeting Summary

This symposium was focused on reviewing androgen deprivation therapy (ADT) in prostate cancer, highlighting the implications of this therapy in clinical practice and including a focus on the cardiovascular (CV) risk associated with ADT therapy.

Download (PDF, 87KB)

Comments are closed.